Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Jonathan W. Friedberg, Jeff Sharman, John Sweetenham, Patrick B. Johnston, Julie M. Vose, Ann LaCasce, Julia Schaefer-Cutillo, Sven De Vos, Rajni Sinha, John P. Leonard, Larry D. Cripe, Stephanie A. Gregory, Michael P. Sterba, Ann M. Lowe, Ronald Levy, Margaret A. Shipp

Research output: Contribution to journalArticlepeer-review

579 Scopus citations

Fingerprint Dive into the research topics of 'Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds